Samedi, 21 Octobre 2017
Dernières nouvelles
Principale » Valeant Pharmaceuticals International, Inc. (VRX) Lowered to Hold at Vetr Inc

Valeant Pharmaceuticals International, Inc. (VRX) Lowered to Hold at Vetr Inc

13 Octobre 2017

They presently have a $14.26 target price on the specialty pharmaceutical company's stock.

A number of hedge funds have recently modified their holdings of VRX. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.87 by $1.93. HC Wainwright reaffirmed a hold rating and set a $17.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Wednesday, October 4th. Cantor Fitzgerald maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Monday, October 2 with "Buy" rating. Finally, Wells Fargo & Company reaffirmed an underperform rating and set a $8.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Saturday, September 30th. Five investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $17.71. Thomas J Herzfeld Advisors Inc owns 0.01% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 1,300 shares. (VRX) has the market capitalization of $5 Billion. The stock is now moving above its 20-Day Simple Moving Average of 10.6% with a 50-Day Simple Moving Average of 20.1 percent. The share last price represents downtick move of -43.09% in value from company's 52-Week high price and shows 66.41% above change in value from its 52-Week low price. (NYSE:VRX) are -5.08%; -1.98% for the month; -19.78% for the last quarter; 45.89% for the past six-months; and -39.05% for the last 12 months. Stifel Nicolaus reaffirmed a "buy" rating and set a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th.

Now we take a performance look how Valeant Pharmaceuticals International, Inc. The company had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion.

Sa première sortie depuis l'annonce de sa troisième grossesse — Kate Middleton
Elle est enceinte?Je n'arrive pas à croire qu'elle soit enceinte, elle est trop maigre? Mais depuis, la Duchesse de Cambridge a disparu des radars due à son état de santé.

For this year, Matador Resources Company (NYSE:MTDR) is performing 0.31%. Analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

VRX has been the topic of several recent analyst reports. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and global copyright and trademark legislation. Bessemer Gp stated it has 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). IBC downgraded the stock to "Sector Perform" rating in Tuesday, October 20 report. The stock was purchased at an average cost of $13.90 per share, for a total transaction of $278,000.00. Following the completion of the transaction, the director now owns 77,479 shares in the company, valued at $1,110,274.07. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Gulf International Bank UK Ltd raised its stake in shares of Valeant Pharmaceuticals Intl by 1.1% in the first quarter. PNC Financial Services Group Inc. increased its position in shares of Valeant Pharmaceuticals International by 33.7% in the first quarter. Canada Pension Plan Investment Board now owns 2,104,500 shares of the specialty pharmaceutical company's stock valued at $36,525,000 after buying an additional 2,096,100 shares during the period. It is negative, as 53 investors sold Valeant Pharmaceuticals Intl Inc shares while 76 reduced holdings. Its last month's stock price volatility remained 2.27% which for the week stands at 3.01%. Renaissance Technologies LLC acquired a new position in shares of Valeant Pharmaceuticals International in the 2nd quarter valued at $41,574,000. World Asset Management Inc now owns 21,502 shares of the specialty pharmaceutical company's stock worth $237,000 after buying an additional 328 shares during the period.

The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a huge mover today! The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).